{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T03:09:52Z","timestamp":1723518592789},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,30]]},"DOI":"10.7759\/cureus.20030","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T19:00:44Z","timestamp":1638298844000},"source":"Crossref","is-referenced-by-count":1,"title":["Endometrial Surveillance in Tamoxifen and Letrozole Treated Breast Cancer Patients"],"prefix":"10.7759","author":[{"given":"Adhari","family":"AlZaabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa","family":"AlAmri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadeer","family":"ALAjmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manhal","family":"Allawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatema","family":"Muhanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqaia","family":"Alabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatema","family":"AlBusaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaima","family":"AlGhafri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman  A","family":"Al-Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al Baimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.2962","article-title":"Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)","volume":"9","author":"Hu R","year":"2015","unstructured":"Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). Oncol Lett. 2015, 9:1495-501. 10.3892\/ol.2015.2962","journal-title":"Oncol Lett"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.11.747","article-title":"Tamoxifen: the herald of a new era of preventive therapeutics","volume":"89","author":"Jordan CV","year":"1997","unstructured":"Jordan CV. Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst. 1997, 89:747-9. 10.1093\/jnci\/89.11.747","journal-title":"J Natl Cancer Inst"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies C","year":"2011","unstructured":"Davies C, Godwin J, Gray R, et al.. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011, 378:771-84. 10.1016\/S0140-6736(11)60993-8","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S43763","article-title":"Tamoxifen for women at high risk of breast cancer","volume":"6","author":"Nazarali SA","year":"2014","unstructured":"Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer. Breast Cancer (Dove Med Press). 2014, 6:29-36. 10.2147\/BCTT.S43763","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer","volume":"356","author":"Bergman L","year":"2000","unstructured":"Bergman L, Beelen MLR, Gallee MPW, et al.. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet. 2000, 356:881-7. 10.1016\/S0140-6736(00)02677-5","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92692-1","article-title":"Risk of endometrial cancer after tamoxifen treatment of breast cancer","volume":"343","author":"van Leeuwen FE","year":"1994","unstructured":"van Leeuwen FE, Van den Belt-Dusebout AW, et al.. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994, 343:448-52. 10.1016\/S0140-6736(94)92692-1","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study","volume":"97","author":"Swerdlow AJ","year":"2005","unstructured":"Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005, 97:375-84. 10.1093\/jnci\/dji057","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.19.1654","article-title":"Tamoxifen therapy for breast cancer and endometrial cancer risk","volume":"91","author":"Bernstein L","year":"1999","unstructured":"Bernstein L, Deapen D, Cerhan JR, et al.. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999, 91:1654-62. 10.1093\/jnci\/91.19.1654","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/bcr7","article-title":"Endogenous hormones and the aetiology of breast cancer","volume":"1","author":"Key TJ","year":"1999","unstructured":"Key TJ, Verkasalo PK. Endogenous hormones and the aetiology of breast cancer. Breast Cancer Res. 1999, 1:18-21. 10.1186\/bcr7","journal-title":"Breast Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors \u03b1 and \u03b2","volume":"138","author":"Kuiper GJM","year":"1997","unstructured":"Kuiper GJM, Carlsson B, Grandien K, Enmark E, Ha\u0308ggblad J, Nilsson S, Gustafsson J. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors \u03b1 and \u03b2. Endocrinology. 1997, 138:863-70. 10.1210\/endo.138.3.4979","journal-title":"Endocrinology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314525688","article-title":"Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats","volume":"42","author":"Schweikart KM","year":"2014","unstructured":"Schweikart KM, Eldridge SR, Safgren SL, et al.. Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats. Toxicol Pathol. 2014, 42:1188-96. 10.1177\/0192623314525688","journal-title":"Toxicol Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb11339.x","article-title":"A study on the effect of a single dose of tamoxifen on uterine hyperaemia and growth in the rat","volume":"92","author":"Marshall K","year":"1987","unstructured":"Marshall K, Senior J. A study on the effect of a single dose of tamoxifen on uterine hyperaemia and growth in the rat. Br J Pharmacol. 1987, 92:429-35. 10.1111\/j.1476-5381.1987.tb11339.x","journal-title":"Br J Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher B","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, et al.. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996, 88:1529-42. 10.1093\/jnci\/88.21.1529","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.9.827","article-title":"Pathology of endometrium treated with tamoxifen","volume":"47","author":"Ismail SM","year":"1994","unstructured":"Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994, 47:827-33. 10.1136\/jcp.47.9.827","journal-title":"J Clin Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-2-199907200-00009","article-title":"Surveillance for endometrial cancer in women receiving tamoxifen","volume":"131","author":"Suh-Burgmann EJ","year":"1999","unstructured":"Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med. 1999, 131:127-35. 10.7326\/0003-4819-131-2-199907200-00009","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007245.pub3","article-title":"Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen","author":"Dominick S","year":"2015","unstructured":"Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochra Databa Syst Rev. 2015, 10.1002\/14651858.CD007245.pub3","journal-title":"Cochra Databa Syst Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29332","article-title":"Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors","volume":"121","author":"Chlebowski RT","year":"2015","unstructured":"Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015, 121:2147-55. 10.1002\/cncr.29332","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/316243","article-title":"Changing trends of breast cancer survival in Sultanate of Oman","volume":"2011","author":"Kumar S","year":"2011","unstructured":"Kumar S, Burney IA, Al-Ajmi A, Al-Moundhri MS. Changing trends of breast cancer survival in Sultanate of Oman. J Oncol. 2011, 2011:316243. 10.1155\/2011\/316243","journal-title":"J Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/uog.1704","article-title":"How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding","volume":"24","author":"Smith-Bindman R","year":"2004","unstructured":"Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasou Obstet Gynecol. 2004, 24:558-65. 10.1002\/uog.1704","journal-title":"Ultrasou Obstet Gynecol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.168.3.9057510","article-title":"Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings","volume":"168","author":"Hann LE","year":"1997","unstructured":"Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. Am J Roentgen. 1997, 168:657-61. 10.2214\/ajr.168.3.9057510","journal-title":"Am J Roentgen"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2008.0020","article-title":"The effect of tamoxifen on the genital tract","volume":"8","author":"Polin SA","year":"2008","unstructured":"Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Canc Imag. 2008, 8:135-45. 10.1102\/1470-7330.2008.0020","journal-title":"Canc Imag"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.20.3464","article-title":"Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound","volume":"18","author":"Gerber B","year":"2000","unstructured":"Gerber B, Krause A, M\u00fcller H, et al.. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000, 18:3464-70. 10.1200\/JCO.2000.18.20.3464","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2013.01.014","article-title":"Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women","volume":"22","author":"Aydiner A","year":"2013","unstructured":"Aydiner A. Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast. 2013, 22:121-9. 10.1016\/j.breast.2013.01.014","journal-title":"Breast"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00587-5","article-title":"Uterine side effects of tamoxifen: a need for systematic pretreatment screening","volume":"91","author":"Bekliere M","year":"1998","unstructured":"Bekliere M, Charles A, Galant C, et al..  Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet. Gynecol. 1998, 91:40-44. 10.1016\/S0029-7844(97)00587-5","journal-title":"Obstet. Gynecol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.06.009","article-title":"Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review","volume":"38","author":"Iqbal J","year":"2012","unstructured":"Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012, 38:318-28. 10.1016\/j.ctrv.2011.06.009","journal-title":"Cancer Treat Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.6.456","article-title":"Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years","volume":"93","author":"Stewart HJ","year":"2001","unstructured":"Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001, 93:456-62. 10.1093\/jnci\/93.6.456","journal-title":"J Natl Cancer Inst"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies C","year":"2013","unstructured":"Davies C, Pan H, Godwin J, et al.. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013, 381:805-16. 10.1016\/S0140-6736(12)61963-1","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00441-4","article-title":"Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen","volume":"91","author":"Fung MFK","year":"2003","unstructured":"Fung MFK, Reid A, et al.. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol. Oncol. 2003, 91:154-59. 10.1016\/S0090-8258(03)00441-4","journal-title":"Gynecol. Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"Committee opinion no. 601: tamoxifen and uterine cancer","volume":"123","author":"Committee on Gynecologic Practice","year":"2014","unstructured":"Committee on Gynecologic Practice. Committee opinion no. 601: tamoxifen and uterine cancer. Obstet Gynecol. 2014, 123:1394-97. 10.1097\/01.AOG.0000450757.18294.cf","journal-title":"Obstet Gynecol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/71241-endometrial-surveillance-in-tamoxifen-and-letrozole-treated-breast-cancer-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:18Z","timestamp":1707507138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/71241-endometrial-surveillance-in-tamoxifen-and-letrozole-treated-breast-cancer-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.20030","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}